Sera Prognostics Inc (SERA) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Sera Prognostics Inc stock (SERA) is currently trading at $2.03. Sera Prognostics Inc PS ratio (Price-to-Sales) is 874.34. Analyst consensus price target for SERA is $5.00. WallStSmart rates SERA as Sell.
- SERA PE ratio analysis and historical PE chart
- SERA PS ratio (Price-to-Sales) history and trend
- SERA intrinsic value — DCF, Graham Number, EPV models
- SERA stock price prediction 2025 2026 2027 2028 2029 2030
- SERA fair value vs current price
- SERA insider transactions and insider buying
- Is SERA undervalued or overvalued?
- Sera Prognostics Inc financial analysis — revenue, earnings, cash flow
- SERA Piotroski F-Score and Altman Z-Score
- SERA analyst price target and Smart Rating
Sera Prognostics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Sera Prognostics Inc (SERA) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, institutional own.. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Sera Prognostics Inc (SERA) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
57.05% held by institutions, strong professional interest
Supporting Valuation Data
Sera Prognostics Inc (SERA) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Revenue declining -58.30%, a shrinking business
Very expensive at 874.3x annual revenue
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Sera Prognostics Inc (SERA) Detailed Analysis Report
Overall Assessment
This company scores 23/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Institutional Own.. Valuation metrics including Price/Book (0.86) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (874.34) suggest expensive pricing. Growth concerns include Revenue Growth at -58.30%, which may limit upside. Profitability pressure is visible in Return on Equity at -51.80%, Operating Margin at -89540.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -51.80% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -58.30% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SERA Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SERA's Price-to-Sales ratio of 874.34x trades 21% below its historical average of 1100.17x (47th percentile). The current valuation is 72% below its historical high of 3161.65x set in Jan 2025, and 307% above its historical low of 214.81x in Jan 2023. Over the past 12 months, the PS ratio has compressed from ~1729.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Sera Prognostics Inc (SERA) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Sera Prognostics Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 81,000 with 58% decline year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Debt-to-equity ratio of 0.03 indicates a conservative balance sheet with 4M in cash.
Spending 3970% of revenue (3M) on R&D, reinforcing its commitment to innovation and future growth.
Revenue contracted 58% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -6M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Sera Prognostics Inc.
Bottom Line
Sera Prognostics Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Sera Prognostics Inc(SERA)
NASDAQ
HEALTHCARE
MEDICAL DEVICES
USA
Sera Prognostics Inc. is a pioneering healthcare company focused on advancing maternal-fetal health through innovative diagnostic solutions. Leveraging its proprietary biomarker platform, Sera developed the PreTRM test to assess the risk of preterm birth, enabling timely clinical interventions that can significantly improve pregnancy outcomes. With a strong emphasis on collaboration with healthcare providers, Sera is poised to lead the prenatal diagnostics market, enhancing both maternal health and overall societal well-being. The company's dedication to innovation not only aims to foster healthier pregnancies but also seeks to generate long-term value for its investors.